Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

First line of the email MUST contain NCT # and Site #.


BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Back

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Nottingham Belfast Northern Ireland Birmingham Canterbury Kent Lancashire Blackpool London London Oxford Portsmouth Sutton Wolverhampton

Medical Conditions

Multiple Myeloma
Neoplasms, Plasma Cell

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2022 Mar 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Intervention Arm Group : Daratumumab in combination with Iberdomide and dexamethasone - Dose 1;Daratumumab in combination with Iberdomide and dexamethasone - Dose 2;Daratumumab in combination with Iberdomide and dexamethasone - Dose 3;Daratumumab in combination with dexamethasone and bortezomib;

Intervention Type : DRUG
Intervention Description : Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

Intervention Arm Group : Daratumumab in combination with Iberdomide and dexamethasone - Dose 1;Daratumumab in combination with Iberdomide and dexamethasone - Dose 2;Daratumumab in combination with Iberdomide and dexamethasone - Dose 3;

Intervention Type : DRUG
Intervention Description : Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.

Intervention Arm Group : Daratumumab in combination with dexamethasone and bortezomib;

Intervention Type : DRUG
Intervention Description : Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle

Intervention Arm Group : Daratumumab in combination with Iberdomide and dexamethasone - Dose 1;

Intervention Type : DRUG
Intervention Description : Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle

Intervention Arm Group : Daratumumab in combination with Iberdomide and dexamethasone - Dose 2;

Intervention Type : DRUG
Intervention Description : Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle

Intervention Arm Group : Daratumumab in combination with Iberdomide and dexamethasone - Dose 3;

Intervention Type : DRUG
Intervention Description : Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8

Intervention Arm Group : Daratumumab in combination with dexamethasone and bortezomib;

Intervention Type : DRUG
Intervention Description : Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.

Intervention Arm Group : Daratumumab in combination with dexamethasone and bortezomib;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Local Institution - 702
    Nottingham
    Nottinghamshire
    NG5 1PB
  • Local Institution - 705
    Belfast Northern Ireland
    BT9 7AD
  • Local Institution - 700
    Birmingham
    B15 2TH
  • Local Institution - 707
    Canterbury Kent
    CT1 3NG
  • Local Institution - 704
    Lancashire Blackpool
    FY3 8NR
  • Local Institution - 701
    London
    NW1 2BU
  • Local Institution - 709
    London
    SE1 9RT
  • Local Institution - 706
    Oxford
    OX3 7LE
  • Local Institution - 711
    Portsmouth
    PO6 3LY
  • Local Institution - 713
    Sutton
    SM2 5PT
  • Local Institution - 708
    Wolverhampton
    WV10 0QP

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain NCT # and Site #.



The study is sponsored by Celgene



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04975997
Last updated 15 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top